“Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus”, Vascular Pharmacology, September 10, 2024

Abstract “Despite the innovations introduced in the 2022 European Society of Cardiology/European Respiratory Society Guidelines on Pulmonary Hypertension, risk discrimination and management of pulmonary arterial hypertension patients at intermediate risk still represents a grey zone. Additionally, clinical evidence derived from currently available studies is limited. This expert panel survey intends to aid physicians in choosing […]

“Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus”, Vascular Pharmacology, September 10, 2024 Read Post »

“Integrating the patient perspective into future pulmonary hypertension clinical trials”, European Society of Cardiology Annual Congress 2024, talk by Pisana Ferrari, member of the ESC Patient Forum

The European Society of Cardiology’s Congress is the foremost gathering in the field of cardiology worldwide. This year’s edition took place in London from 30.8-1.9, 2024, and counted 31,700 participants from 162 countries, including 5,400 faculty and presenters, representatives of the National Cardiac Societies and industry partners. Pisana Ferrari, the Alliance for Pulmonary Hypertension’s Secretary

“Integrating the patient perspective into future pulmonary hypertension clinical trials”, European Society of Cardiology Annual Congress 2024, talk by Pisana Ferrari, member of the ESC Patient Forum Read Post »

Could artificial intelligence contribute to earlier diagnosis of pulmonary arterial hypertension? Recent research shows promising results, “Managed Healthcare Executive”, August 20, 2024

Over the past decade, significant strides have been made in diagnosing and treating pulmonary hypertension, driven by updated criteria and new medications. However, timely diagnosis remains a major challenge, with many patients facing long delays, often waiting years and consulting multiple doctors before receiving an accurate diagnosis. Journalist and healthcare writer Jared Kaltwasser has recently

Could artificial intelligence contribute to earlier diagnosis of pulmonary arterial hypertension? Recent research shows promising results, “Managed Healthcare Executive”, August 20, 2024 Read Post »

For far too long, medicine has ignored the valuable insights that patients have into their own diseases. It is time to listen, “Aeon Psyche”, August 5, 2024

An article titled “Empowering patient research” which was recently published on the Aeon Psyche newsletter on August 5, 2024, discusses the challenges faced by patients with chronic illnesses and disabilities in the healthcare system, particularly in research and academia. The article advocates for the inclusion of patients as active participants in medical research, arguing that

For far too long, medicine has ignored the valuable insights that patients have into their own diseases. It is time to listen, “Aeon Psyche”, August 5, 2024 Read Post »

Recent study suggests that resistin could be a key biomarker and therapeutic target in pulmonary arterial hypertension, “Respiratory Research”, June 6, 2024

The findings of study which aimed to evaluate the potential for using resistin as a genetic and biological marker for disease severity and survival in pulmonary arterial hypertension were published on June 6, 2024 in “Pulmonary Research”. Resistin is an adipose-derived hormone (similar to a cytokine). The researchers collected biospecimens, clinical, and genetic data for 1.121 adults

Recent study suggests that resistin could be a key biomarker and therapeutic target in pulmonary arterial hypertension, “Respiratory Research”, June 6, 2024 Read Post »

Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus, “Respiratory Medicine”

Oral treprostinil is a prostacyclin analogue approved to treat pulmonary arterial hypertension (PAH). A study analysing the practical management of oral treprostinil in patients with pulmonary arterial hypertension has been published on “Respiratory Medicine” Volume 231, 107734, September 2024. The article is based on results of the ADAPT and EXPEDITE trials and expert consensus. The

Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus, “Respiratory Medicine” Read Post »

Aerovate Therapeutics announces that its pulmonary arterial hypertension candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial

Aerovate Therapeutics has announced that its pulmonary arterial hypertension (PAH) candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial. The Phase IIb portion of the IMPAHCT trial aimed to assess three different doses of AV-101, a novel dry powder inhaled formulation of imatinib. The primary endpoint tested

Aerovate Therapeutics announces that its pulmonary arterial hypertension candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial Read Post »

Colleen Brunetti, pulmonary arterial hypertension patient and patient advocate, speaks about her experience with the condition and clinical trials, May 2024

Colleen Brunetti, Past Chair of the Board of the Pulmonary Hypertension Association, speaks about her experience with the condition and taking part in clinical trials in this video, published on the European Lung Foundation YouTube channel. Read more about Colleen and her book “Defining the new normal: A guide to becoming more than your diagnosis”

Colleen Brunetti, pulmonary arterial hypertension patient and patient advocate, speaks about her experience with the condition and clinical trials, May 2024 Read Post »

The US Food and Drug Administration (FDA) issues guidance to medical product sponsors to ensure greater inclusivity in clinical trials, June 26, 2024

The U.S. Food and Drug Administration (FDA) has issued a draft guidance titled “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies.” This guidance is aimed at assisting medical product sponsors in submitting “Diversity Action Plans” for certain clinical studies. These plans are designed to enhance the enrollment of historically

The US Food and Drug Administration (FDA) issues guidance to medical product sponsors to ensure greater inclusivity in clinical trials, June 26, 2024 Read Post »

Interesting analysis of the prognostic value of the “Multicomponent Improvement” (MCI) endpoint in patients with pulmonary arterial hypertension (PAH) treated with sotatercept

The Multicomponent Improvement” (MCI) endpoint is a composite endpoint measuring improvement in 6-minute walk distance, reduction or maintenance of low N-terminal pro-BNP levels, and improvement or maintenance of WHO functional class I or II. The American Journal of Respiratory and Critical Care Medicine has published the abstract of a session at the American Thoracic Society

Interesting analysis of the prognostic value of the “Multicomponent Improvement” (MCI) endpoint in patients with pulmonary arterial hypertension (PAH) treated with sotatercept Read Post »

“Fundamentals of Genetic Testing”, a live webinar organised by the Pulmonary Hypertension Association (PHA) in collaboration with with partners TBX4life and Fundación Contra la Hipertensión Pulmonar, June 11, 2024

The Pulmonary Hypertension Association (PHA) is holding a webinar of “Fundamentals of Genetic Testing“ on Tuesday, June 11, at 2 p.m. EDT/ 6 p.m. UTC in collaboration with TBX4Life and Fundación Contra la Hipertensión Pulmonar Featured topics include The webinar will be available in English and Spanish. Speakers Harm Jan Bogaard, MD, PhDProfessor of Experimental Pulmonary MedicinePulmonologist, Department

“Fundamentals of Genetic Testing”, a live webinar organised by the Pulmonary Hypertension Association (PHA) in collaboration with with partners TBX4life and Fundación Contra la Hipertensión Pulmonar, June 11, 2024 Read Post »

Gossamer Bio and Chiesi Group announce global collaboration to develop and commercialise seralutinib in pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD)

Gossamer Bio and Chiesi Group have announced a a global collaboration agreement to develop seralutinib, an inhaled investigational drug for the treatment of pulmonary arterial hypertension. Seralutinib is currently being investigated in the ongoing global Phase 3 trial, PROSERA, for pulmonary arterial hypertension. This collaboration further enhances the resources and expertise devoted to seralutinib and

Gossamer Bio and Chiesi Group announce global collaboration to develop and commercialise seralutinib in pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD) Read Post »

Can dietary changes treat pulmonary hypertension? A new study suggests that some foods may affect blood vessel stiffening in pulmonary hypertension

The Cell metabolism journal has published a study by the University of Pittsburgh researcher Stephen Chan, MD, PhD, and colleagues from the team of Thomas Bertero at the Université Côte d’Azur in France, which explores the relation between diet and pulmonary hypertension. The findings reveal that hypertensive pulmonary blood vessel cells have an “appetite” for two

Can dietary changes treat pulmonary hypertension? A new study suggests that some foods may affect blood vessel stiffening in pulmonary hypertension Read Post »

A groundbreaking medical innovation known as the “sentinel skin flap” may hold the key to early detection of rejection in lung transplant patients

Could a medical innovation known as the “sentinel skin flap” hold the key to early detection of rejection in lung transplant patients? This pioneering technique, currently under investigation in a trial conducted by the University of Oxford and NHS Blood and Transplant, offers new hope for enhancing post-transplant care. Leading the charge in this groundbreaking trial is Henk Giele,

A groundbreaking medical innovation known as the “sentinel skin flap” may hold the key to early detection of rejection in lung transplant patients Read Post »

United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin

United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin Application n° US17072430, December 12, 2023, Publication Number: US11839631B2. The news was reported in the Magazine “Pharmaceutical Technology, April 4, 2024. To be followed! Read more at this link on the

United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin Read Post »

The Holland Hybrid Heart consortium receives €11 M grant for its research on a robotic heart for people with severe heart failure

The Holland Hybrid Heart (HHH) consortium brings together universities, higher professional education, companies and patient organisations. The Dutch pulmonary hypertension association Stichting Pulmonale Hypertensie is part of this consortium. The consortium has been awarded a grant of 11 million euros from the National Science Agenda for its research on a soft implantable robotic heart for

The Holland Hybrid Heart consortium receives €11 M grant for its research on a robotic heart for people with severe heart failure Read Post »

Gas-filled balloon implanted in main pulmonary artery to alleviate right ventricle workload tested in pulmonary hypertension

The Aria CV Pulmonary Hypertension System is an implantable gas-filled balloon that is introduced percutaneously in the main pulmonary artery to alleviate the excessive workload on the right heart that results in right heart failure. An article published in the European Journal of Heart Failure on March 13, 2024 titled “Efficacy and safety of the

Gas-filled balloon implanted in main pulmonary artery to alleviate right ventricle workload tested in pulmonary hypertension Read Post »

The Phase 3 clinical trial to evaluate the safety and efficacy of oral inhalation of seralutinib for pulmonary arterial hypertension is enrolling

The PROSERA Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the oral Inhalation of seralutinib for the treatment of pulmonary arterial hypertension is currently enrolling. The PROSERA study’s objective is to understand the effect of seralutinib on specific pathways in the body that lead to the inflammation, proliferation and fibrosis

The Phase 3 clinical trial to evaluate the safety and efficacy of oral inhalation of seralutinib for pulmonary arterial hypertension is enrolling Read Post »

Phase 1 clinical trial on a treprostinil skin patch for pulmonary arterial hypertension due to start shortly

Corsair Pharma has developed a proprietary transdermal patch intended to provide consistent blood levels of treprostinil, a drug currently administered via a 24/7 infusion pump (sub-cutaneous or intra-venous, see this link for more details), by delivering an inactive prodrug, which crosses the skin, enters the blood, and converts rapidly to treprostinil in the liver. Since

Phase 1 clinical trial on a treprostinil skin patch for pulmonary arterial hypertension due to start shortly Read Post »

Cereno Scientific announces FDA approval for expanded access to investigational pulmonary arterial hypertension drug CS1

Cereno Scientific announced on January 31, 2024 that it has received approval from the US Food and Drug Administration (FDA) for expanded access to the investigational drug CS1 in the ongoing Phase II trial for pulmonary arterial hypertension (PAH). This program allows patients who completed the Phase II to continue CS1 therapy. Positive outcomes from

Cereno Scientific announces FDA approval for expanded access to investigational pulmonary arterial hypertension drug CS1 Read Post »

TRANSLATE »
Scroll to Top